(thirdQuint)Compassionate Use of Campath-1H in Treating Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic Leukemia.

 OBJECTIVES: I.

 Expand access to Campath-1H for patients with refractory prolymphocytic leukemia or chronic lymphocytic leukemia.

 OUTLINE: Patients receive Campath-1H IV over 2 hours on days 1, 3, and 5.

 Treatment repeats weekly for 4-12 weeks in the absence of disease progression or unacceptable toxicity.

 PROJECTED ACCRUAL: Not specified.

 Compassionate Use of Campath-1H in Treating Patients With Refractory Prolymphocytic Leukemia or Chronic Lymphocytic Leukemia@highlight

RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.

 Compassionate use refers to providing a drug to a patient on humanitarian grounds before the drug has received official approval.

 PURPOSE: Compassionate use of Campath-1H in treating patients who have refractory prolymphocytic leukemia or chronic lymphocytic leukemia.

